Compare Stocks: SPTX, INDV, OGN, and ARQT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$26.92	$25.77	$16.71 ▼ $31.77	$3.38B	1.5	3.26 million shs	2.04 million shs
INDV Indivior	$35.82	$37.12	$22.56 ▼ $42.81	$4.23B	0.82	1.95 million shs	1.09 million shs
OGN Organon & Co.	$13.74 +0.0%	$13.67	$5.69 ▼ $13.78	$3.61B	1.52	2.66 million shs	1.39 million shs
SPTX Seaport Therapeutics	$21.52	$22.87	$14.85 ▼ $28.38	$1.15B	N/A	256,833 shs	192,796 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	0.00%	+6.22%	+13.20%	+0.60%	+53.22%
INDV Indivior	0.00%	+2.69%	+2.72%	-13.18%	+49.75%
OGN Organon & Co.	0.00%	+0.37%	-0.25%	+1.48%	+34.59%
SPTX Seaport Therapeutics	0.00%	+0.61%	-10.48%	-4.44%	+2,151,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$26.92	$25.77	$16.71 ▼ $31.77	$3.38B	1.5	3.26 million shs	2.04 million shs
INDV Indivior	$35.82	$37.12	$22.56 ▼ $42.81	$4.23B	0.82	1.95 million shs	1.09 million shs
OGN Organon & Co.	$13.74 +0.0%	$13.67	$5.69 ▼ $13.78	$3.61B	1.52	2.66 million shs	1.39 million shs
SPTX Seaport Therapeutics	$21.52	$22.87	$14.85 ▼ $28.38	$1.15B	N/A	256,833 shs	192,796 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	0.00%	+6.22%	+13.20%	+0.60%	+53.22%
INDV Indivior	0.00%	+2.69%	+2.72%	-13.18%	+49.75%
OGN Organon & Co.	0.00%	+0.37%	-0.25%	+1.48%	+34.59%
SPTX Seaport Therapeutics	0.00%	+0.61%	-10.48%	-4.44%	+2,151,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.67	Moderate Buy	$35.57	32.14% Upside
INDV Indivior	2.71	Moderate Buy	$45.17	26.09% Upside
OGN Organon & Co.	1.71	Reduce	$11.40	-17.00% Downside
SPTX Seaport Therapeutics	2.50	Moderate Buy	$38.57	79.24% Upside

Current Analyst Ratings Breakdown

Latest SPTX, INDV, OGN, and ARQT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	SPTX Seaport Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$46.00
9/25/2026	SPTX Seaport Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/24/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
9/24/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
9/10/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
9/8/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/4/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/26/2026	SPTX Seaport Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$32.00
8/21/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/20/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/20/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$376.07M	9.00	N/A	N/A	$1.55 per share	17.37
INDV Indivior	$1.24B	3.41	$2.72 per share	13.17	($0.78) per share	-45.92
OGN Organon & Co.	$6.22B	0.58	$5.80 per share	2.37	$2.89 per share	4.75
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$16.14M	$0.21	128.20	23.61	N/A	6.15%	15.05%	6.51%	10/27/2026 (Estimated)
INDV Indivior	$210M	$2.79	12.84	9.35	N/A	26.65%	-283.11%	36.85%	10/29/2026 (Estimated)
OGN Organon & Co.	$187M	$0.77	17.84	3.99	1.27	3.41%	88.97%	6.03%	11/9/2026 (Estimated)
SPTX Seaport Therapeutics	-$74.88M	-$12.12	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest SPTX, INDV, OGN, and ARQT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	ARQT Arcutis Biotherapeutics	$0.0551	$0.11	+$0.0549	$0.11	$118.85 million	$129.86 million
8/3/2026	Q2 2026 & Merger	INDV Indivior	$0.8690	$1.15	+$0.2810	$4.90	$306.23 million	$343.00 million
8/3/2026	Q2 2026	SPTX Seaport Therapeutics	-$0.71	-$1.78	-$1.07	-$1.78	N/A	N/A
6/30/2026	Q2 2026	INDV Indivior	N/A	$5.75	N/A	$4.90	N/A	$343.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.58%	N/A	10.39%	N/A
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest SPTX, INDV, OGN, and ARQT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/17/2026	INDV Indivior	special	$8.13		10/30/2026	10/30/2026	11/6/2026
7/31/2026	OGN Organon & Co.	quarterly	$0.02	0.58%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.46	2.92	2.67
INDV Indivior	N/A	0.84	0.66
OGN Organon & Co.	8.43	1.95	1.44
SPTX Seaport Therapeutics	N/A	18.00	18.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
INDV Indivior	60.33%
OGN Organon & Co.	77.43%
SPTX Seaport Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
INDV Indivior	0.74%
OGN Organon & Co.	1.62%
SPTX Seaport Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	354	125.69 million	113.88 million	Optionable
INDV Indivior	838	118.03 million	117.16 million	Not Optionable
OGN Organon & Co.	10,000	262.61 million	258.36 million	Not Optionable
SPTX Seaport Therapeutics	58	53.53 million	N/A	N/A

SPTX, INDV, OGN, and ARQT Headlines

Recent News About These Companies

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Stock Has Average Price Target of $38.57

48 minutes ago | americanbankingnews.com

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Stock Has Consensus Target Price of $38.57

50 minutes ago | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Upgraded at Raymond James Financial

3 hours ago | americanbankingnews.com

Seaport Therapeutics, Inc. $SPTX Shares Newly Acquired by State Street Corp

September 27 at 3:28 AM | marketbeat.com

Seaport Therapeutics, Inc. : Raymond James réitère son opinion positive sur le titre

September 26 at 8:20 AM | zonebourse.comZ

Raymond James initiates coverage of Seaport Therapeutics at strong buy

September 26 at 8:20 AM | msn.com

Seaport Therapeutics (NASDAQ:SPTX) Stock Lifted to "Strong-Buy" by Raymond James Financial

September 26 at 6:29 AM | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Up - Here's Why

September 25 at 10:59 AM | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Up - Here's What Happened

September 15, 2026 | marketbeat.com

Seaport Therapeutics to Participate in September Investor Conferences

September 14, 2026 | finance.yahoo.com

Seaport Therapeutics to Participate in September Investor Conferences

September 14, 2026 | businesswire.com

The Manufacturers Life Insurance Company Acquires New Stake in Seaport Therapeutics, Inc. $SPTX

September 14, 2026 | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Stock Price Up 4.6% - Should You Buy?

September 10, 2026 | marketbeat.com

HC Wainwright Reaffirms Buy Rating for Seaport Therapeutics (NASDAQ:SPTX)

September 10, 2026 | marketbeat.com

Seaport Therapeutics Says GlyphAllo Shows no Next-Morning Driving Impairment in Phase 1 Trial

September 9, 2026 | finance.yahoo.com

Seaport Therapeutics Reports Positive Topline Results From Phase 1 Driving Simulation Trial Of GlyphAllo In Healthy Volunteers

September 9, 2026 | marketscreener.comM

Seaport Reports Positive GlyphAllo Driving Trial Results In Healthy Volunteers

September 9, 2026 | rttnews.com

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

September 9, 2026 | businesswire.com

Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

September 9, 2026 | finance.yahoo.com

Citadel Advisors LLC Takes Position in Seaport Therapeutics, Inc. $SPTX

September 8, 2026 | marketbeat.com

Braidwell LP Takes $10.86 Million Position in Seaport Therapeutics, Inc. $SPTX

September 3, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPTX, INDV, OGN, and ARQT Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$26.92 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$26.86 -0.06 (-0.20%)

As of 09/25/2026 07:30 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Indivior NASDAQ:INDV

$35.82 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$36.15 +0.33 (+0.93%)

As of 09/25/2026 07:57 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Organon & Co. NYSE:OGN

$13.74 +0.01 (+0.04%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$13.70 -0.04 (-0.25%)

As of 09/25/2026 07:30 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Seaport Therapeutics NASDAQ:SPTX

$21.52 0.00 (0.00%)

As of 09/25/2026 04:00 PM Eastern

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPTX, INDV, OGN, and ARQT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPTX, INDV, OGN, and ARQT Earnings

Compare Dividends

Latest SPTX, INDV, OGN, and ARQT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPTX, INDV, OGN, and ARQT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPTX, INDV, OGN, and ARQT Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

Indivior NASDAQ:INDV

Organon & Co. NYSE:OGN

Seaport Therapeutics NASDAQ:SPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPTX, INDV, OGN, and ARQT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPTX, INDV, OGN, and ARQT Earnings

Compare Dividends

Latest SPTX, INDV, OGN, and ARQT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPTX, INDV, OGN, and ARQT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPTX, INDV, OGN, and ARQT Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

Indivior NASDAQ:INDV

Organon & Co. NYSE:OGN

Seaport Therapeutics NASDAQ:SPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools